HC Wainwright Issues Pessimistic Forecast for Unicycive Therapeutics (NASDAQ:UNCY) Stock Price

Posted by George Bondi on Sep 29th, 2026

Unicycive Therapeutics (NASDAQ:UNCY – Get Free Report) had its target price reduced by research analysts at HC Wainwright from $15.00 to $13.00 in a note issued to investors on Tuesday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. HC Wainwright’s price target indicates a potential upside of 188.25% from the stock’s current price.

Other analysts have also issued research reports about the company. Guggenheim restated a “buy” rating and issued a $25.00 price objective (down from $37.00) on shares of Unicycive Therapeutics in a research note on Thursday, August 13th. Zacks Research upgraded Unicycive Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Wednesday, August 19th. Weiss Ratings reissued a “sell (d-)” rating on shares of Unicycive Therapeutics in a report on Friday, September 4th. B. Riley Financial restated a “buy” rating and issued a $20.00 price target (down from $22.00) on shares of Unicycive Therapeutics in a research note on Wednesday, August 12th. Finally, Benchmark reaffirmed a “speculative buy” rating and set a $15.00 price target (up from $13.00) on shares of Unicycive Therapeutics in a report on Thursday, August 20th. Five equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Unicycive Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $18.25.

View Our Latest Stock Analysis on Unicycive Therapeutics

Unicycive Therapeutics Trading Down 2.8%

Shares of Unicycive Therapeutics stock traded down $0.13 during trading on Tuesday, hitting $4.51. 1,290,779 shares of the stock were exchanged, compared to its average volume of 920,126. The stock has a market capitalization of $125.60 million, a price-to-earnings ratio of -2.60 and a beta of 1.79. The company has a fifty day moving average price of $5.17 and a 200-day moving average price of $6.32. Unicycive Therapeutics has a 1-year low of $3.93 and a 1-year high of $8.74.

Unicycive Therapeutics (NASDAQ:UNCY – Get Free Report) last issued its earnings results on Wednesday, August 12th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.47) by $0.41. Equities research analysts forecast that Unicycive Therapeutics will post -1.17 EPS for the current fiscal year.

Hedge Funds Weigh In On Unicycive Therapeutics

Large investors have recently made changes to their positions in the company. Dimensional Fund Advisors LP acquired a new stake in Unicycive Therapeutics during the 1st quarter worth approximately $940,000. Seven Fleet Capital Management LP grew its holdings in Unicycive Therapeutics by 85.6% in the 2nd quarter. Seven Fleet Capital Management LP now owns 103,400 shares of the company’s stock valued at $521,000 after buying an additional 47,700 shares in the last quarter. Bank of New York Mellon Corp acquired a new position in Unicycive Therapeutics in the 2nd quarter valued at $248,000. Bank of America Corp DE increased its position in Unicycive Therapeutics by 19,327.6% during the 1st quarter. Bank of America Corp DE now owns 29,530 shares of the company’s stock worth $194,000 after buying an additional 29,378 shares during the period. Finally, Renaissance Technologies LLC bought a new position in Unicycive Therapeutics during the 1st quarter worth $161,000. Institutional investors own 40.42% of the company’s stock.

Key Unicycive Therapeutics News

Here are the key news stories impacting Unicycive Therapeutics this week:

Positive Sentiment: Unicycive announced that it has resubmitted its New Drug Application for oxylanthanum carbonate (OLC), an investigational phosphate binder for dialysis patients with chronic kidney disease. The company expects the FDA to accept the application within 30 days and assign a new PDUFA decision date approximately six months after resubmission, restoring a potential regulatory path for its lead product. Unicycive Therapeutics Announces Resubmission of New Drug Application for Oxylanthanum Carbonate
Neutral Sentiment: Multiple law firms reiterated that investors who purchased UNCY securities between December 29, 2025, and June 29, 2026, have until November 2, 2026, to seek appointment as lead plaintiff in a pending federal securities class action. These notices are largely duplicative and do not represent new judicial findings. Faruqi & Faruqi Unicycive Securities Class Action Notice
Negative Sentiment: The lawsuit-related announcements allege that Unicycive resubmitted the OLC application without inspecting its third-party manufacturer’s facility for current good manufacturing practice compliance. The complaints also contend that the company had promoted an FDA decision and potential commercial launch despite manufacturing concerns linked to an earlier Complete Response Letter. If proven, the allegations could create legal costs, reputational damage, and additional uncertainty around OLC’s approval timeline. Bronstein Gewirtz Grossman Unicycive Class Action Notice

Unicycive Therapeutics Company Profile

(Get Free Report)

Unicycive Therapeutics, Inc is a clinical-stage biotechnology company focused on developing treatments for patients with kidney disease. The company’s lead product candidate is oxylanthanum carbonate, an oral phosphate binder being developed to treat hyperphosphatemia, or elevated phosphate levels, in patients with chronic kidney disease, including those receiving dialysis.

Oxylanthanum carbonate is designed to bind dietary phosphate in the gastrointestinal tract, helping reduce the amount of phosphate absorbed into the bloodstream.